Limited Time Offer
Get $1000 towards your
first investment
Start investing in private markets with Linqto – your access to disruptive startups and pre-IPO companies.
*Terms and conditions apply. See details
IsoPlexis, founded in 2013 and headquartered in Branford, Connecticut, is a company that develops a diagnostic platform to accelerate immunology research and therapeutic development. Their innovative technology aims to enhance the implementation of new therapeutic technologies in the field of immunology. With a total funding of $213 million raised, IsoPlexis has demonstrated significant investor interest in its potential.
In March 2023, IsoPlexis was acquired by Berkeley Lights, marking a significant milestone in the company's journey. This acquisition may have implications for any potential future public offering, as IsoPlexis is now part of a larger organization. However, it's important to note that we currently don't have any specific information or reports regarding IsoPlexis' IPO prospects.
For investors interested in the biotechnology and immunology sectors, IsoPlexis represents a company with a focus on cutting-edge diagnostic technologies. While the possibility of investing directly in IsoPlexis stock may be limited due to its acquisition, interested parties may want to keep an eye on Berkeley Lights, the company that acquired IsoPlexis, for potential investment opportunities in this space.
As with any investment decision, it's crucial for potential investors to conduct thorough research and consider various factors, including market conditions, company performance, and industry trends, before making any investment choices.
Get $1000 towards your
first investment
*Terms and conditions apply. See details
While IsoPlexis's IPO prospects remain uncertain, investors eager to gain exposure to innovative biotech companies don't have to wait. At Linqto, we offer members access to interests in pre-IPO private companies, including potential leaders in the life sciences and biotechnology sectors. Our platform allows you to diversify your portfolio with lower minimum investments in emerging industry pioneers like IsoPlexis, potentially benefiting from their growth before they go public.
*These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO. The information provided above is based on current online discussions and is not intended as investment advice. Linqto does not endorse or guarantee the accuracy of this information, and we strongly recommend conducting your own research or consulting with a professional advisor before making any investment decisions. Linqto cannot be held liable for any investment outcomes resulting from the use of this information.
